As of Nov 12, 2026, Colossal Biosciences's estimated valuation is $5.25B; its last round was a Series C+ on Sep 18, 2025, raising $120M at a $10.3B valuation.
Estimated Valuation$5.25B
Valuation As OfNov 12, 2026
Latest Raise$120M
Latest RoundSeries C+
Latest Funding Valuation$10.3B
Latest Funding DateSep 18, 2025
About Colossal Biosciences
Colossal Biosciences is a biotechnology company working on 'de-extinction,' using gene editing to bring back species like the woolly mammoth and dodo while building conservation tech for endangered animals.
Funding rounds
| Round | |||
|---|---|---|---|
| Sep 18, 2025 | Series C+ | $120M | $10.3B |
| Jan 15, 2025 | Series C | $310.58M | $10.26B |
| Feb 3, 2023 | Series B | $173.8M | $1B |
| Mar 9, 2022 | Series A | $65.43M | — |
| May 1, 2021 | Seed-1 | $9.02M | — |
Perpetual markets
No perpetual markets available.
Token issuers
No token issuer markets available.
Frequently asked questions
What is Colossal Biosciences's estimated valuation?
As of Nov 12, 2026, Colossal Biosciences's latest tracked valuation estimate is $5.25B.
When was Colossal Biosciences's last funding round?
Colossal Biosciences's latest tracked funding round was a Series C+ on Sep 18, 2025, raising $120M at a $10.3B valuation.
Valuation and funding data updated Nov 13, 2026, 9:56 PM UTC.
Market data updated Nov 13, 2026, 9:56 PM UTC.